These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 20855989)

  • 1. Transitioning issues in adolescent to young adult hemophilia patients with inhibitors: an approach for a growing population.
    Young G
    Blood Coagul Fibrinolysis; 2010 Sep; 21 Suppl 1():S7-10. PubMed ID: 20855989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unmet needs in the transition to adulthood: 18- to 30-year-old people with hemophilia.
    Quon D; Reding M; Guelcher C; Peltier S; Witkop M; Cutter S; Buranahirun C; Molter D; Frey MJ; Forsyth A; Tran DB; Curtis R; Hiura G; Levesque J; de la Riva D; Compton M; Iyer NN; Holot N; Cooper DL
    Am J Hematol; 2015 Dec; 90 Suppl 2():S17-22. PubMed ID: 26619193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors.
    Singer ST; Addiego JE; Reason DC; Lucas AH
    Thromb Haemost; 1996 Jul; 76(1):17-22. PubMed ID: 8819245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitor treatment in haemophilias A and B: inhibitor diagnosis.
    DiMichele DM
    Haemophilia; 2006 Dec; 12 Suppl 6():37-41; discussion 41-2. PubMed ID: 17123392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives of patients with cystic fibrosis on preventive counseling and transition to adult care.
    Zack J; Jacobs CP; Keenan PM; Harney K; Woods ER; Colin AA; Emans SJ
    Pediatr Pulmonol; 2003 Nov; 36(5):376-83. PubMed ID: 14520719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From boy to man: recommendations for the transition process in haemophilia.
    Young G
    Haemophilia; 2012 Jul; 18 Suppl 5():27-32. PubMed ID: 22757681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing the pediatric patient and the adolescent/adult transition.
    Valentino LA; Santagostino E; Blanchette V; van den Berg M
    Semin Thromb Hemost; 2006 Jun; 32 Suppl 2():28-31. PubMed ID: 16804833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate.
    Peerlinck K; Arnout J; Di Giambattista M; Gilles JG; Laub R; Jacquemin M; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1997 Jan; 77(1):80-6. PubMed ID: 9031454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes, quality of life, and impact of hemophilia on young adults (aged 18-30 years) with hemophilia.
    Witkop M; Guelcher C; Forsyth A; Hawk S; Curtis R; Kelley L; Frick N; Rice M; Rosu G; Cooper DL
    Am J Hematol; 2015 Dec; 90 Suppl 2():S3-10. PubMed ID: 26619194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of patients with hemophilia A and inhibitors to factor FVIII with cimetidine.
    Ambriz Fernandez R; Quintana Gonzalez S; Martinez Murillo C; Dominguez Garcia V; Rodriguez Moyado H; Collazo Jaloma J
    Arch Med Res; 1996; 27(1):15-8. PubMed ID: 8867361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic fibrosis in adolescents and young adults.
    Nasr SZ
    Adolesc Med; 2000 Oct; 11(3):589-603. PubMed ID: 11060556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing risk factors: prevention of inhibitors in haemophilia.
    Chambost H
    Haemophilia; 2010 Mar; 16 Suppl 2():10-5. PubMed ID: 20132333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.
    Gouw SC; van den Berg HM
    Semin Thromb Hemost; 2009 Nov; 35(8):723-34. PubMed ID: 20169509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between factor VIII genotype and inhibitor development in hemophilia A.
    Fakharzadeh SS; Kazazian HH
    Semin Thromb Hemost; 2000; 26(2):167-71. PubMed ID: 10919409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent improvements in the clinical treatment of coagulation factor inhibitors.
    Franchini M; Lippi G
    Semin Thromb Hemost; 2009 Nov; 35(8):806-13. PubMed ID: 20169517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meeting increased demand.
    Blair A
    Jpn Hosp; 2004 Jul; (23):19-22. PubMed ID: 19195249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immune coagulation disorders (excluding antiphospholipid syndrome].
    Arai M
    Rinsho Byori; 2001 Oct; 49(10):1000-4. PubMed ID: 11769464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of anti-human and anti-porcine factor VIII antibody titers in patients with hemophilia].
    Windyga J; Rzymkiewicz L; Lopaciuk S
    Acta Haematol Pol; 1996; 27(1):27-31. PubMed ID: 8629440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.